IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to know the difference between protein profiles (multi-analyte profile) of PH1 patients, idiopathic hypercalciuria (IH) patients and PH1 patients 'siblings. Idiopathic hypercalciuria is a less severe kidney disease that PH1, which also leads to the formation of kidney stones.

The aim is to identify patterns of discriminating markers associated with primary hyperoxaluria type 1 (PH1) that will significantly improve clinical diagnosis and prognosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?

NCT07201701

Nephrolithiasis

NOT_YET_RECRUITING

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)

NCT06511349

Type 1 Primary Hyperoxaluria

RECRUITING EARLY_PHASE1

Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria

NCT00588120

Enteric Hyperoxaluria Hyperoxaluria

COMPLETED PHASE1

Impact of Parathyroidectomy on Renal Function

NCT04798092

Primary Hyperparathyroidism

UNKNOWN

Hydroxyproline Influence on Oxalate Metabolism

NCT02038543

Hyperoxaluria

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hyperoxaluria Type 1 Idiopathic Hypercalciuria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with primary hyperoxaluria, type 1 (PH1-Cohort A); OR
* Confirmed with AGXT mutation analysis (PH1-Cohort A)
* Diagnosed with idiopathic hypercalciuria (IHC- Cohort B);
* Potential subject diagnosed with PH1 or IH and has both data entered into the registry and has matched, archived random and 24-hour urine specimens obtained prior to any treatment intervention OR is consented and enrolled into the registry or this specific study during the program;
* Healthy siblings of PH1 patients known not to have PH or any another stone disease or chronic disease will be consented and enrolled into this study through the local sites where their sibling is being treated for PH1 (this study meets the criteria for expedited review through local or central IRBs);
* Healthy non-sibling controls known not to have PH or any another stone disease or chronic disease (Healthy Control-Cohort C);
* There is no upper or lower limit to the pediatric age range of enrolling infant, children and adolescent subjects, although it is understood that accurate and complete 24-hour urine collection in very young children and infants will be problematic and will be seriously considered in advance of individual patient or healthy controls enrollment;
* eGFR (Glomerular Filtration Rate) \> 60 mL/min x 1.73 m2 with PH1 and IH patient cohorts matched by mean eGFR from their initial study (or registry) enrollment/ data collection.

Exclusion Criteria

* Unwilling to provide written parent consent or adolescent assent to enroll into the International Registry or this study;
* Potential PH1, hypercalciuria, or siblings of PH1 patients with other chronic or acute illness or disease that could potentially confound proteomic results;
* Healthy intra-familial siblings unwilling to provide a blood sample for serum creatinine;
* Unwilling to provide urine specimens or permit data abstraction for the registry or this study.
* Not covered by, or having the right to, Social Security

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes